arrow
K

Kith Pradhan

Montefiore Einstein Comprehensive Cancer Center
H指数:42
被引数:1.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Graft-versus-host disease prophylaxis with abatacept plus intermediate dose cyclophosphamide for GVHD prophylaxis after peripheral blood stem transplantation: a single institution study

阿巴西特联合中剂量环磷酰胺预防异基因造血干细胞移植后移植物抗宿主病:一项单中心研究

2026-07-270
PRE
Chromatin rewiring of β-globin and MYC enhancers by TGF-β1 drives defective erythropoiesis

TGF-β1通过重塑β-球蛋白和MYC增强子染色质驱动缺陷性红细胞生成

2026-05-130
OAAI
Environmental Pollution Triggers Inflammation In Vivo and is Associated With Higher Risk MDS in an Urban Cohort

环境污染物在体内引发炎症,并与城市人群中的高风险MDS相关。

2025-11-010
OAAI
Splicing regulatory dynamics for precision analysis and treatment of heterogeneous leukemias

异质性白血病精准分析与治疗的剪接调控动力学

2025-05-070
PRE
Degrading SMARCA2/4 Relieves the Differentiation Block in AML Via Chromatin Alterations Affecting S100A8/9

通过影响S100A8/9的染色质改变,降解SMARCA2/4可解除急性髓系白血病(AML)的分化阻滞

BLOOD
IF23.1
2024-11-051
PRE
Promising Safety and Efficacy Data for Peginterferon Alfa-2a (PEG-IFN) and Bictegravir/Emtricitabine/Tenofovir Alafenamide (Biktarvy) in a North American Adult T-Cell Leukemia Lymphoma (NA-ATLL) Cohort of Patients

Peginterferon Alfa-2a(PEG-IFN)和Bictegravir/Emtricitabine/Tenofovir Alafenamide(Biktarvy)在北美成人T细胞白血病/淋巴瘤(NA-ATLL)患者队列中的安全性和有效性数据表现出前景。

BLOOD
IF23.1
2024-11-050
PRE
Post-Transplantation Cyclophosphamide and Abatacept Graft-Versus-Host-Disease Prophylaxis Shows Improved Outcomes in North American Adult T-Cell Leukemia/Lymphoma

移植后环磷酰胺和阿巴西特移植物抗宿主病预防显示出在北美成人T细胞白血病/淋巴瘤中改善的结局

BLOOD
IF23.1
2024-11-050
PRE
Venetoclax Alone or in Combination Shows Promising Activity in Preclinical Models and Clinical Cases of Relapsed/Refractory North American Adult T-Cell Leukemia Lymphoma

Venetoclax单药或联合用药在北美成人T细胞白血病/淋巴瘤的复发/难治性预临床模型和临床病例中显示出有希望的抗肿瘤活性。

BLOOD
IF23.1
2024-11-050
PRE
Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: a phase 1b/2 clinical trial and correlative analyses

谷氨酰胺酶抑制联合氮杂胞苷治疗骨髓增生异常综合征: 1b/2期临床试验及相关分析

2024-09-190
PRE
Immunotherapy-resistant acute lymphoblastic leukemia cells exhibit reduced CD19 and CD22 expression and BTK pathway dependency
2024-02-201
OAAI
Study of efficacy and longevity of immune response to third and fourth doses of COVID-19 vaccines in patients with cancer: A single arm clinical trial
2023-03-2815
OA